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The prodromal stage of Alzheimer’s Disease, amnestic mild cognitive 
impairment, is characterized by subjective and objective memory impairment beginning 
with episodic memory. Few treatments have been identified to effectively slow disease 
progression to dementia. Meditation is an emerging novel treatment to improve deficits in 
subjects with these progressive cognitive impairments. Meditation and other novel 
treatments are critical for prolonging patients’ independence, reducing caregiver burden, 
and healthcare costs. This study will examine the effectiveness of an eight-week 
intervention using two meditation methods and two control groups on cognition and 
mood in participants with amnestic mild cognitive impairment. The primary outcome is 
episodic memory. Secondary outcomes include verbal fluency, executive function, 
working memory, and mood symptoms. We believe meditation interventions are low-
cost, safe, easily implemented interventions that could improve cognition and mood 
symptoms in patients with amnestic mild cognitive impairment through induced changes 
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CHAPTER ONE-INTRODUCTION 
I. Alzheimer’s Disease 
I.a Epidemiology 
 
 Alois Alzheimer first described Alzheimer’s Disease in 1906 while presenting a 
51 year old patient with progressive cognitive decline.1 Now, the disease bearing his 
name affects 36 million people worldwide and is the most common cause of dementia.2 
This number is projected to increase to 115.4 million by 2050 due to the globally 
increasing population over 65. Additionally, it is suggested that half of people with AD 
are never diagnosed, so the scope is likely much greater than stated. AD most commonly 
presents in the seventh decade of life, and two-thirds of cases are in women. Earlier-onset 
cases are less common and are often due to familial genetic mutations.1 Its prodromal 
state, amnestic mild cognitive impairment, is the target of many pharmaceutical and non-
pharmaceutical interventions aimed at slowing cognitive decline and preserving 
independence. This study focuses on this population. 
I.b Risk Factors  
 
While age is the greatest risk factor for AD; family history and the presence of the 
APOE4 gene are other non-modifiable risk factors.2 Known modifiable risk factors 
include cardiovascular disease, hypertension, hyperlipidemia, sedentary lifestyle, obesity, 
smoking, diabetes, insomnia, and fewer years of education. Growing evidence from the 




I.c Diagnosis of Cognitive Impairments 
 
AD is a progressive neurodegenerative disease with hallmark neuropathology.4 
This includes -amyloid protein fragments causing plaques to accumulate on neurons’ 
exterior while tau proteins accumulate within neurons, leading to dysfunction, 
deregulation, and neuronal death. While these biomarkers of AD are well established and 
correlate to clinical severity, AD remains a clinical diagnosis, for which the National 
Institute on Aging and Alzheimer’s Association proposed new diagnostic criteria in 
2011.2 The new guidelines divide AD into three separate stages that are described below: 
preclinical AD, mild cognitive impairment due to AD, and dementia due to AD. This 
study will adapt these criteria to the definition and diagnosis of aMCI. 
I.c.i Preclinical AD 
 
Preclinical AD features positive biomarkers including increased levels of tau or p-
tau in cerebral spinal fluid, decreased cerebral spinal fluid ab 1-42 levels,5 or changes on 
magnetic resonance imaging (MRI), single-photon emission computed tomography 
(SPECT) and positron emission tomography (PET) imaging.2,6,7 However, the patient 
exhibits no subjective or objective memory complaints. The biomarkers have been found 
up to twenty years before a person exhibits memory symptoms.2 Due to the lack of 
subjective or objective memory impairments, preclinical AD is largely a diagnostic 
category utilized by research studies. 
I.c.ii aMCI 
 
aMCI features subjective and objective impairments in one or more areas of 
memory, learning, and recall that do not preclude the person from functioning 
independently.2 Of all aMCI cases, 50% progress to dementia within 3-4 years. While 
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symptoms vary, many individuals with aMCI first experience a loss of ability to 
remember newly learned information, often described as short term memory loss.2 In this 
study, individuals with aMCI were selected because of the proposed effectiveness of 
disease modifying treatments administered before the cognitive decline has advanced into 
dementia.1,2 Additionally, treatment in this group aims to prolong their high quality of life 
by preserving independent functioning.  
I.c.iii Dementia due to AD 
 
Dementia due to AD is diagnosed when clinical criteria for aMCI progresses to 
include impairments in daily functioning, such as the inability to manage finances or 
medication.2 Disorientation to time and place, while retaining orientation to person is also 
common, as well as problems with planning, judgment, withdrawal, apathy, depression, 
and misplacing belongings. Eventually, incapacitation leads to development of secondary 
infections, such as aspiration pneumonia or falls, which can lead to death. In the United 
States, AD is the sixth leading cause of death across all ages.  
I.d Treatment 
 
 The Food and Drug Administration has approved five medications for AD, but 
none can slow or stop the ultimate disease progression.2 The efficacy of these 
medications has been based on delaying a patient’s institutionalization or requirement of 
a full time aide by one year. Given that this is the benchmark for pharmaceutical 
effectiveness, there remains ample room for behavioral, non-pharmaceutical 
interventions, which may delay, or allow compensation for, the disease processes. Drug 
development cost, trial longevity, and the blood brain barrier are current barriers to more 
effective drug development. Studies have increasingly focused on the possibility of 
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delaying expression of AD clinical symptoms with non-pharmacologic therapies 
including meditation, exercise, sleep, yoga, and specialized nutrition.8  These alternative 
therapies also primarily aim to delay the decline of cognitive function, preserve 
independence, and improve quality of life for patients and their caregivers.  
II. Meditation  
 
Meditation is thousands of years old practice traditionally used in religious or 
spiritual settings that has more recently been employed in Western cultures to enhance 
overall well-being.3 While there are many variations and types of meditation, one uniting 
feature is the goal of focused, self-regulation of attention as well as open and accepting 
experience of the present moment. Meditation practice aims to engage the mind in goal-
directed activity and regulation of attention and awareness while the body is in a 
hypometabolic state.9 Meditation interventions have been studied in patients with chronic 
pain, fibromyalgia,10 cancer,11 coronary artery disease, and depression on a variety of 
outcomes including stress, cognition, attention, anxiety, and depression.8,12 Meditation 
has recently been studied as a promising non-pharmaceutical intervention for subjective 
cognitive decline, aMCI, AD, and other dementias, though the pathophysiology behind 
its effects remains unclear.2-4  
II.a Kirtan Kriya Meditation 
 
Kirtan Kriya (KK) meditation is an established, safe, easy to learn, and effective 
meditation intervention studied in subjects with and without memory complaints, aMCI, 
and AD and other dementias.3 It is the most common meditation intervention in the 
literature in subjects with aMCI and AD, and thus one of the meditation interventions for 
this study. 
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KK meditation is a simple chanting meditation performed over 12 minutes13 
(Appendix A). Chanting meditations focus on the repetition of speech, or mantras, to 
produce a meditative state. KK combines the mantra “saa, taa, naa, maa” with repetitive 
matched finger movements touching the thumb to the first, second, third, and fourth 
fingers in time with the words. The mantra is repeated spoken, whispered, and silently for 
two minutes each, then silently, whispered, and spoken for a total of 12 minutes of 
practice.  
II.b Mindfulness Meditation 
 
 Another form of meditation, Mindfulness (MFL), teaches the subject to focus on 
the present, while they accept other stimuli that enter the mind, before dismissing them.14 
Practitioners focus on a physical element, such as breathing, to help maintain focus and 
control of thoughts moving through the body (Appendix B). Mindfulness Based Stress 
Reduction (MBSR) is an intensive intervention that requires longer periods of home 
meditation practice as well as group meetings.8,15 MBSR has shown positive outcomes on 
wellbeing, acceptance of situations,16 improved sleep,17 decreased morning cortisol 
levels, and improved executive functioning and working memory18 in subjects with and 
without cognitive impairment.  
The effects of MBSR in AD and aMCI have been investigated, but the procedure 
of MBSR is much more intensive and too dissimilar from the KK protocol for this 
proposed study. Instead, this study’s MFL intervention is a brief 12-minute intervention 
similar to the KK intervention. To our knowledge, this type of meditation intervention 
has never been studied in populations with aMCI. By including a MFL intervention 
similar to the KK meditation in time and duration, we aim to explore a possible role for 
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other types of brief meditation for people with aMCI. The MFL intervention will have 
subjects focus on their breathing, while they direct their thoughts in an L-shaped pattern 
through the top of their head and out of their mouth as they exhale. 
III. Proposed Mechanism of Action 
 
This study aims to expand on the current literature that has shown that meditation 
is an effective and safe intervention for people with aMCI. While this study will not 
pursue imaging, it draws from previous results to suggest a pathophysiology behind the 
hypotheses of meditation’s impact on a brain with aMCI. Specifically, the default mode 
network (DMN) can be modified and strengthened through meditation.  
The DMN is a group of anatomically separate regions that show functional 
interconnectedness through synchronized patterns of activation, especially at rest,19,20 and 
when a person is not engaged in a goal-oriented task.21 The proposed regions of the DMN 
include the medial prefrontal cortex (mPFC), posterior cingulate cortex (PCC), anterior 
cingulate cortex (ACC), precuneus, inferior parietal cortex, and lateral temporal cortex.22-
24 The PCC is thought to be the posterior hub that communicates to areas important for 
memory encoding, retrieval, and formation like the hippocampus while the mPFC is 
thought to be the anterior hub of activity.21  
Selective areas of DMN activation are associated with mind wandering, 
daydreaming, self-memory, self-reflection, prospective thought, and thinking in the 
perspective of others.19-21 The DMN is also shown to be overall more active during tasks 
of episodic memory, such as autobiographical thought, which is compromised in aMCI 
and AD.23 Concurrently, areas of the DMN are selectively deactivated during processes 
requiring attention and concentration. Research has found that experienced meditators 
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deactivate the regions of the DMN associated with mind wandering, and have better 
performance on measures of attention and concentration.14,25,26 As many daily tasks 
involve aspects of simultaneous use of these functions, the DMN is normally partially, 
but selectively activated and deactivated.22 Interruptions and deregulations of these 
patterns of activation and deactivation are thought to compose the cognitive disturbances 
that cause the aMCI and AD symptoms.27 
III.a DMN Disruption 
 
DMN disruption is found in AD, and is a target for pharmacological and 
alternative therapy interventions.20,28  The patterns of disruption found in AD are so 
consistent and specific that it is a proposed biomarker for AD and aMCI studies.19,21 
Additionally, abnormal disruption and activation patterns of the DMN are found on 
functional-magnetic resonance imaging (fMRI) studies before objective or subjective 
memory symptom onset.21,29 It is important to note that it is the deregulation of the DMN 
that is thought to cause the impairments of cognition, not just a global increase or 
decrease in activity of DMN function. For example, the areas associated with mind 
wandering and rumination show increased activation in AD and aMCI, while there is 
decreased activation in areas responsible for episodic memory retrieval.23  
IV. Statement of the Problem  
 
Currently there are few validated treatments for aMCI. Recent studies have focused 
on novel, non-pharmaceutical treatments to delay expression, and potentially progression 
of the disease towards AD. Meditation is one such novel intervention under investigation, 
with the aim to potentially improve cognitive function and delay institutionalization. The 
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current literature on meditation is limited in scope to KK meditation and MBSR in 
subjects with aMCI.  
The studies reviewed were generally underpowered, used small sample sizes or 
limited to pilot or proof of concept studies, and lacked adequate control groups.13,27,30-32 
Several studies used active controls, engaging the subjects in a task of passive relaxation 
like music or book listening,30,31 or psychoeducation classes.32 While this strategy is 
helpful for separating effects unique to meditation compared to passive relaxation or 
active control, it does not allow comparison to an inactive control. This study will employ 
a wait list control as a way to control for the possible effects of music listening.33 
V. Goals and Objectives 
V.a Goals  
 
The purpose of this study is to examine the effects of eight-week Kirtan Kriya and 
Mindfulness meditation interventions on percent change from baseline performance of 
pre- and post-measures of episodic memory, verbal fluency, working memory, executive 
function, anxiety, and depression, compared to an active (music listening) and inactive 
control. The primary outcome is episodic memory, specifically verbal memory, as it is 
classically impaired in aMCI.34,35 The California Verbal Learning Test-II (CVLT-II),36 a 
neuropsychological test, will operationalize verbal memory in this study with four 
dependent variables: semantic categorization, total learning (trials 1-5), long delayed 
recall, and cued long delayed recall. 
Secondary outcomes of this study focus on other impairments common in aMCI 
including verbal fluency, working memory, executive function, and symptoms of 
depression and anxiety. Verbal fluency will be evaluated with phonemic fluency, using 
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the letters C, F, and L, as well as semantic (category-animal) fluency.36 Working memory 
will be evaluated with the WAIS-IV Digit Span Test, where subjects must recall lists of 
numbers both forwards and backwards in sequence.27 Executive function will be 
evaluated with the Trails Making Test (TMT) A and B, which evaluates attention span, 
task switching ability, and processing speed.37 Two scales validated for use in elderly 
populations will be used for evaluation of mood symptoms. Depression symptoms will be 
evaluated by the Geriatric Depression Scale (GDS),38 and anxiety symptoms with the 
Rating Anxiety in Dementia (RAID) Scale, which is additionally validated in elderly 
people with memory impairments and dementia.39  
This study will compliment and expand the current literature by comparing KK 
and MFL meditation to two controls, one active and one inactive, on neuropsychological 
tests that reflect areas most affected by aMCI. Results will shed light on the relative 
effectiveness and feasibility of each meditation practice, which will provide impetus for 
future research on meditation in aMCI populations. Use of both an active and inactive 
control has not been attempted to our knowledge. Additionally, we aim to further validate 
meditation as an effective, safe therapy for aMCI and strengthen evidence for the role of 
the DMN in aMCI pathophysiology and treatment.  
V.b Objectives  
 
1. Compare KK meditation intervention to music listening and wait-list 
controls on measures of episodic memory using the CVLT-II. 
2. Compare MFL meditation intervention to music listening and wait-list 
controls on measures of episodic memory using the CVLT-II. 
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3. Compare secondary outcomes of verbal fluency, working memory, 
executive function, depression, and anxiety using Animals Fluency, Letter 
C, F, and L Fluency, WAIS-IV Digit Span Test, TMT A and B, GDS, and 
RAID measures, respectively, amongst all groups. 
VI. Hypothesis 
 
Subjects with aMCI are known to have DMN dysfunction,20,27 while meditation is 
known to improve DMN function. These improvements in DMN function have been 
linked to improve memory performance. Thus, we hypothesized that an eight-week KK 
or MFL intervention will improve scores, as determined by percent change from baseline, 
on measures of episodic memory, and secondary outcomes of verbal fluency, working 
memory, executive function, depression, and anxiety compared to music listening control 
and inactive control groups in subjects with aMCI, as a function of improved DMN 
functioning. We expect the effect to be greater between the meditation groups and 




A. KK—Kirtan Kriya; 12-minute meditation involving the repetitive movement of 
fingers to thumb and repetition of phrase “saa, taa, naa, maa” out loud, whispered, 
and silently in 2 minute intervals 
B. MFL—Mindfulness; Meditation focused on creating and maintaining awareness 
of one’s surroundings, especially body, breath, and mind, and accepting thoughts 
and intrusions without judgment 
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C. CVLT-II—California Verbal Learning Test-II; neuropsychological test of 
episodic (verbal) memory, including semantic categorization, immediate recall, 
and delayed recall  
D. RAID—Rating Anxiety in Dementia; Scale adapted for demented or cognitively 
impaired individuals to rate feelings and symptoms of anxiety in daily living 
E. GDS—Geriatric Depression Scale; Scale for use in the elderly to rate feelings of 
depression, apathy, and risk for harm or self-harm  
F. Animals Category Fluency—Measure of semantic fluency; subject names as 
many animals as they can in one minute 
G. Letter C, F, L Fluency—Measure of phonemic fluency; subjects name as many 
words that begin with the letter C, F, or L as they can in separate one minute trials 
H. WAIS-IV Digit Span Test—Measure of working memory, specifically mental 
flexibility and processing; subjects must recall lists of numbers forwards and 
backwards. 
I. Trail Making Tests A and B—Measure of frontal executive function, including 
attention span, task switching ability, and processing 
J. DMN—Default Mode Network; interconnected brain regions that show increased 
activity at rest. Includes posterior cingulate cortex, precuneus, anterior cingulate 
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CHAPTER TWO—REVIEW OF THE LITERATURE 
I. Introduction: Literature Search Criteria 
 
 A systematic literature review was conducted from August 2015 through May 
2016 using Ovid (MEDLINE), PubMed@Yale, and relevant bibliographies with the 
following key words: mild cognitive impairment, amnestic mild cognitive impairment, 
Alzheimer’s Disease, dementia, meditation, mindfulness meditation, mindfulness, Kirtan 
Kriya, default mode network, non-pharmaceutical intervention, non-pharmaceutical 
cognitive enhancement, neurodegenerative disease, semantic clustering, verbal fluency, 
episodic memory, semantic memory, California Verbal Learning Test-II, Trail Making 
Tests A and B, phonemic fluency, category fluency, anxiety and depression in MCI, 
GDS, RAID, and WAIS-IV Digit Span Test. Articles written in English, using human 
subjects, from 1985 until present were reviewed. Additional articles were sourced from 
relevant journals’ bibliographies. 
II. Review of Meditation Literature  
 
In 2000, aMCI was formally established as the prodromal state of AD dementia.1,2 
aMCI has several characteristic impairments that are the focus of this study. First, 
episodic memory is affected, including poor acquisition, retention, or consolidation of 
information.3 One part of episodic memory is verbal memory, the ability to process, 
retrieve, and recall words. Verbal memory deficiencies are characteristic of aMCI and 
AD,4,5 and performance on measures of verbal memory can distinguish aMCI from other 
MCI subtypes with high specificity and sensitivity.6 For example, people with AD and 
aMCI perform similarly on the CVLT-II compared to those with other subtypes of MCI 
 16 
or healthy participants.7 Verbal memory, operationalized by the CVLT-II (total learning 
trials 1-5, long delayed recall, and cued long delayed recall), is the primary outcome of 
this study. Changes in connectivity of various areas of the DMN are a hypothesized 
source of the cognitive changes seen in these people.3  
Dunn et al. 2014 examined the differences between the DMN of 24 aMCI and 33 
non-aMCI subjects using seed-based resting-fMRI.3 The aMCI subjects showed impaired 
hippocampal and PCC connectivity when data were analyzed according to memory 
testing performance. The researchers found that resting patterns of DMN connectivity can 
distinguish between people with aMCI and non-aMCI. Additionally, they suggested that 
during episodic memory retrieval subjects with aMCI show dysfunction between the 
hippocampus, medial temporal lobe, and PCC, concluding that this dysfunction was 
partially responsible for episodic memory impairment in aMCI. This dysfunctional PCC 
connectivity was also seen by De Vogelaere et al. 20128 and Wang et al. 2013.9 
Collectively, these results suggest that DMN function correlated directly with 
participants’ performance on neuropsychological testing. Concurrently, results of Garces 
et al. 201410 and Jin, Pelak and Cordes11 also showed that DMN changes on imaging 
correlated with deficiencies of memory function, and are detectable before atrophy is 
noticeable on structural MRI. 
The verbal memory impairments of aMCI are compounded by impairment of 
memory retrieval strategies, such as verbal fluency.6 Verbal fluency tasks are measures of 
retrieval networks and are specific and sensitive to select for people with aMCI versus 
other MCI subtypes. Verbal fluency is operationalized here as timed word retrieval, and 
is comprised of phonemic (C,F,L) and category (animals) fluency. 6,7  Mueller et al. 2015 
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followed a cohort (n=283) of cognitively healthy people and people with aMCI for six 
years, and examined verbal fluency, phonemic switching, and semantic. Results 
suggested that individuals who developed aMCI over the following six years had 
significantly lower baseline scores on measures of verbal fluency, with most significant 
differences seen in phonemic and semantic fluency.  
Gardini et al. 2015 conducted a prospective, randomized clinical trial to study the 
effect of aMCI-associated changes in the DMN on semantic memory.12 Subjects were 21 
people with aMCI and 21 demographically matched, healthy elderly controls. At 
baseline, they found that participants with aMCI had evidence of extensive semantic 
memory deterioration, which they attributed to increased, deregulated DMN connectivity 
as seen on fMRI. The study examined category fluency, word association tasks, 
confrontation naming tasks, definition tasks, and reading tasks. The researchers 
concluded that semantic and other impairments of aMCI can be correlated, and likely 
attributed to maladaptive reorganization of the DMN.  
Working memory and executive function are also impaired in patients with 
aMCI,13 and are secondary outcomes of this study. Deregulation of the DMN is thought 
to impair attention and concentration, leading to deficits in tasks of working memory and 
executive function.9 Set shifting ability and working memory are processes modulated 
largely by a frontal neural network, and gray matter of the medial PFC and medial 
temporal cortex are amongst the regions most affected by MCI-associated atrophy.14 
Tsutsumimoto et al. 2015 found an association between gray matter volume and set-
shifting ability as measured by the TMT A and B in 83 elderly people with MCI.14 
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Limitations of this study include its cross-sectional nature, which prevents attributing 
findings to causal relationships.   
III. KK and MFL Meditation  
 
  While there are many forms of meditation practiced worldwide, this study 
focuses on mantra meditation (KK), and MFL meditation. Mantras are repeated phrases 
that are thought to have associated emotional or cognitive effects.15 The KK intervention 
uses the Kundalini yoga mantra of “saa, taa, naa, maa,” which represents beginning, life, 
death, and rebirth. While there is philosophical and spiritual meaning behind this mantra, 
we will not introduce this to our subjects. To evaluate whether a spiritual connection to a 
mantra or meditation is required to produce the described changes, Berkovic-Ohana et al. 
2015 showed that repetitive speech, specifically the repetition of the Hebrew word for 
“one”, can reduce fMRI blood-oxygen-dependent level (BOLD) activation primarily 
centered in areas of the DMN. These results suggest that even subjectively meaningless 
repetitive speech can elicit changes in DMN activity, and subjects do not necessarily need 
to spiritually relate to, or understand the mantra to exhibit cognitive changes. 
III.a Kirtan Kriya—Independent Variable 
 
Kirtan Kriya meditation is the most studied meditation intervention in people with 
AD and MCI. KK is a subtype of transcendental meditation, and involves the use of a 
mantra with synchronized finger-thumb touching. Newberg et al. 2010 was the first to 
use KK meditation in memory-impaired subjects compared to a music listening control 
group.16 They used SPECT imaging to examine cerebral blood flow and 
neuropsychological tests to examine cognitive function in subjects with memory loss. 
Memory impairments ranged from mild and age-associated, to MCI, to diagnosed AD 
 19 
dementia. After an eight-week KK intervention, practiced for 12 minutes per day, the KK 
meditation subjects showed improved verbal fluency, Trails B, and logical memory 
compared to music listening control, but only verbal fluency reached statistical 
significance, with 14% improvement from baseline scores for KK and 3% improvement 
from baseline scores for music listening. 
On SPECT imaging during meditation, KK subjects with memory impairments 
had significantly decreased prefrontal cortex blood flow compared to the music listening 
group.16 These results are similar to those of De Vogelaere et al. 2012,8 who found that 
subjects with aMCI had increased prefrontal cortex activity at rest compared to 
cognitively healthy controls. Together, these results suggest that the aMCI DMN is more 
active at rest than in cognitively healthy people, while meditation enhances the ability to 
selectively decrease the activity of a brain at rest. Drawbacks of the Newberg et al. 2010 
study include small sample size because it was a pilot study (total n=15).16 The study also 
lacked an inactive control, and therefore effects of music listening cannot be excluded as 
a confounder, decreasing the effect size of the KK group outcomes. Finally, this study 
included participants with a range of memory impairments, from age related memory 
decline to known AD dementia, and therefore was not an optimally homogeneous, aMCI 
population. 
III.b Mindfulness—Independent Variable 
 
Two key tenets of MFL meditation are focusing on the present, and accepting 
one’s present experience in a non-judgmental manner.17 As interrupting thoughts enter 
the mind, the MFL meditator acknowledges them and returns his or her focus to the 
meditation object.18 In this study, we employ concentration mindfulness, where the 
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subject focuses on their breath, with a goal on awareness of the present moment. Studies 
have shown mindfulness meditation to be effective in the treatment of pain, addiction, 
anxiety, and depression.19  
Zeidan et al. 2010 used a brief MFL meditation intervention in 24 college students 
and controlled with a book-listening activity for 25 matched controls.18 After four 20-
minute sessions of MFL training (one per day over four days), the MFL group had 
significantly improved scores on Symbol Digit Modalities Test, verbal fluency, hit runs 
on n-back task, and measures of anxiety and fatigue. They did not find significant 
differences on mood scales of depression, anger, confusion, or vigor, forward or 
backward digit spans, or speed n-back task, and attributed this possibly to the short 
duration of intervention.  While the mood scale scores improved, they did not reach 
significance. These results suggested that a brief MFL intervention successfully improved 
neuropsychological testing scores, but raised the possible confounder that the control 
book-listening group was perhaps equally relaxing to MFL meditation, and thus possibly 
prevented results from reaching statistical significance on other mood scores. Toneatto 
and Nguyen 2007 published a review article that supported these concerns, and suggested 
that MBSR techniques are not more effective than active control groups, such as 
relaxation, when compared to an inactive control.20 The Zeidan et al. 2010 results are 
limited in applicability to our proposed study due to the average age of subjects (20 years 
old), and they are cognitively healthy. However, these results support our study in several 
ways.18 First, they found significant effects over a short intervention period (four 
sessions) of training and reported no adverse events. Also, their suggestions further 
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support the use of our inactive and active control group as a way of controlling for the 
possible confounding effects produced due to a cognitively active control group.  
A recent randomized trial by Smart et al. 2016 studied participants with (n=22) 
and without (n=14) subjective cognitive impairment.21 MFL was operationalized 
similarly to MBSR protocols, using eight, weekly, two-hour group sessions and home 
meditation practice along to a CD. Psychoeducation served as the active control, and met 
five weekly two-hour sessions. In this group, participants learned about cognitive decline 
and aging. The researchers noted that these timelines were established protocols for 
MBSR and psychoeducation interventions, and thus the three-week difference should not 
cause confounding effects. One conclusion drawn from the study was that MFL 
participants had improved moment-to-moment attention. Improved attention was 
suggested to potentially help both cognitively health and subjects with cognitive 
impairment delay or slow future decline through better regulation of attention, which 
could possibly help retain newly learned information. One limitation to this study is that 
not all subjects with subjective cognitive impairment progress to aMCI or AD. The 
authors also cite restricted power due to small sample size, though the study was a pilot.  
 Several meditation studies have focused the effects of meditation on attention and 
concentration, which are crucial components of working memory and executive function. 
Tomasino et al. 2016 showed that an eight-week MFL, for 30 minutes, four times per 
week, intervention in 13 cognitively healthy adults had significant effects on activation of 
the right dorsolateral PFC, anterior insula, and left caudate; all areas important for 
focused attention.22 Also, they found deactivation in DMN areas that are typically 
activated during mind-wandering, such as the rostral PFC and right parietal area 3b, with 
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increased activation in the dorsolateral PFC, an area important for attention and 
concentration. While these subjects were cognitively healthy adults, the results suggest 
meditation can reduce activity in areas associated with mind-wandering and improve 
concentration. Pre-intervention fMRIs allowed subjects in this study to serve as their own 
control, which is one limitation of this study, in addition to its small sample size of 13. 
IV. Experienced Meditators  
 
Garrison et al. 2015 showed that experienced meditators (n=20) have decreased 
activity on fMRI in DMN during meditation and rest, compared to meditation-naïve 
controls (n=26).23 This study is limited in applicability to the proposed study because of 
younger mean subject age (44) without memory complaints. Brewer et al. 2011 also 
found that experienced meditators have decreased activation at rest of the posterior 
cingulate cortex and medial prefrontal cortex on fMRI.17 These results collectively 
support the longevity of the effects of meditation on key DMN areas.   
Pagnoni et al. 2008 studied differences in word and non-word identification 
between 12 experienced Zen meditators and 12 matched naïve meditators.24 In between 
tasks, all subjects were instructed to focus on their breath, a task similar to mindfulness 
meditation. While there was no significant difference in reaction time or errors, 
meditators showed decreased BOLD fMRI signals, reaching even to below baseline 
between tasks. Pagnoni et al. suggested the experienced meditators are able to prevent 
mind-wandering that occurs between tasks compared to the controls. In concordance with 
prior literature, the researchers concluded that meditation practice allows for regulation of 
spontaneous mental activity. They suggest that experienced meditators are more efficient 
at refocusing their attention between tasks, and are therefore better at task switching than 
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non-meditators. The researchers point out that due to the difference in position (supine 
vs. seated) in the scanner and how a subject normally meditates could have prevented 
differences in reaction time and performance between groups. Limitations of this study 
include its cross-sectional design, and its small sample size despite being powered with 
the sample size it used. It is limited in generalizability to our study as well because the 
participants are cognitively healthy.   
V. Meditation on Depression and Anxiety  
 
The DMN modulates many intrinsic and self-related processes such as mind-
wandering, day dreaming, and rumination, and is most active at rest and during 
autobiographical tasks in cognitively normal people.3 Increased mind-wandering has been 
associated with decreased performance on cognitive tests, and rumination is linked to 
anxiety and depressive symptoms.18 Depression, apathy, and social withdrawal are 
hallmark symptoms of AD, and negatively impact quality of life of the individual as well 
as the caregivers and family members.25 In a study by Geda et al. 2004, more than half of 
people with aMCI scored significantly higher than age matched controls on measures of 
anxiety and depression.26 Depressive symptoms are also found to be independent risk 
factors for both aMCI development and progression to AD. These and other mood 
symptoms occur significantly more in people with aMCI compared to age-matched 
controls with normal cognition. While research on the temporal relationship between 
depression and anxiety and aMCI is limited, higher depressive symptom scores have been 
associated with poorer baseline memory, and greater decline of memory testing scores in 
a five-year period amongst elderly participants.27 These not only impact quality of life, 
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but also suggest that depression is related to poorer memory functioning. This 
exacerbation of cognitive impairment may hasten decline.  
Feldman et al. 2004 found 59% of subjects with aMCI (n=1,010) suffer from 
neuropsychiatric symptoms, most commonly depression, anxiety, and irritability.28 
Additionally, the presence of these symptoms correlates with increased aMCI severity 
and functional impairment, and increased risk of progressing to AD. Decreasing 
symptoms of anxiety and depression in these patients through meditation would have 
important effects not only for their quality of life, but also potentially partially protect 
against disease progression. 
Several studies have shown that meditation can improve anxiety and depressive 
mood symptoms. Goyal et al. 2014 conducted a meta-analysis of meditation literature in 
cognitively normal subjects and found MFL had moderate supporting evidence of 
improved anxiety, depression, and pain ratings after eight weeks of meditative practice.19 
This review lends support that an eight-week MFL intervention could show an effect that 
reaches significance on mood measures of anxiety and depression. 
Moss et al. 2012 employed a small, randomized clinical trial using an eight-week 
KK meditation compared to a music listening control.29 Fifteen subjects, with varying 
degrees of memory complaints, either meditated or listened to music for 12 minutes a day 
for eight weeks. Subjects were pre-imaged with SPECT to examine cerebral blood flow 
and given a neuropsychological battery was given of a category fluency test, Wechesler 
Adult Intelligence Scale Substitution Test, Logical Memory, and TMT A and B. After the 
intervention, subjects were reimaged and given the same neuropsychological tests. 
Additionally, they used the Profile of Mood States questionnaire to examine subjects’ 
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feelings of tension, depression, anger, fatigue, and confusion. The meditation group 
showed improvement in all measures on the Profile of Mood States, but only fatigue 
reached significance. This study had several limitations, including small sample size of 
15 and varying degrees of memory impairment, leading to a less homogeneous aMCI 
population. For example, seven of their subjects had age related memory impairment. A 
more homogenous population could have improved validity and potentially led to 
different results.  
Lavretsky et al. 2013 examined the effects of an eight-week KK intervention on 
mental health, depressive symptoms, cognition, and telomerase activity in caregivers with 
mild depressive symptoms.30 These 39 caregivers were all caring for people with aMCI, 
AD, or other dementia, and mean age was 60.3. After the eight-week KK intervention, 
they found an improvement in mental health ratings, specifically depression, as rated by 
the Hamilton Rating Scale for Depression (65.2% in KK group vs. 21.2% in relaxation 
group) and the Short Form (36) Health Survey (52.2% KK group vs. 18.7% relaxation 
group). They also found statistically significant improvements on the Trails B Test and 
Mini Mental Status Exam (MMSE) after KK intervention, supporting meditation’s effect 
on executive function and overall cognition. Improvements were noted in the Trails A 
and CVLT tests mean change from baseline, but did not reach significance.  
 This study also examined immune cell telomerase activity, which correlated with 
decreased levels of depression and improved mental health score in the KK group.30 They 
found 43.3% improvement in the KK group, reaching significance compared to 3.7% 
improvement in the relaxation group. Immune cell telomerase activity is inversely 
correlated with levels of chronic stress, and the researchers concluded that meditation is 
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able to specifically improve telomerase activity, cognition, and mental functioning, while 
significantly decreasing depressive symptoms. Limitations of this study include small 
sample size, and lack of cognitive deficits in the study population, which limits 
generalizability to our study’s population.    
VI. Music Listening as an Active Control for Meditation 
 
Music listening will serve as this study’s active control group, which is consistent 
with the majority of literature involving an active control. KK studies that do not use 
music listening often use audiotaped book listening as their control.18 Because our 
primary outcome is verbal memory, we chose not to use book listening to prevent 
possible confounding effects attributed to listening to words.    
The Moss et al. 2012 study compared meditation-naïve subjects undergoing an 
eight-week KK meditation intervention to subjects who listened to 12 minutes of Mozart 
violin concertos.29 In the Newberg et al. 2010 study described above, a second 
comparison group was added (n=5) that listened to Mozart violin concertos for 12 
minutes/day for eight weeks.31 Neither study found significant differences in pre and post 
testing on measures of executive functioning or working memory in the music listening 
groups. However, they did not reach significance on several of their outcomes, which 
could be due to effects of music listening. For example, music therapy has been shown to 
improve verbal fluency in patients with dementia.16 Newberg et al. 2010 suggested the 
future use of an inactive control group for the music listening group to mitigate these 
effects. The proposed study aims to mitigate these possible effects by adding a wait list 
control. 
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VII. Limitations with Current Literature 
 
 The purpose of this study is to compliment and expand the current literature on 
meditation in aMCI. Studies reviewed had small sample sizes, and thus were subject to 
underpowered results and null findings. Given the large number of subjects with aMCI in 
the US, we believe recruiting a larger sample size is feasible within the Yale Memory 
Clinic or Yale Alzheimer’s Disease Research Center.  
 An additional limitation of the current literature surrounds the selected studies’ 
control groups. Controls for the studies reviewed are either active (relaxation or 
book/music listening) or inactive, but to our knowledge no studies have used both. We 
aim to use both a music listening control and an inactive group to control for the possible 
benefits of music listening. For example, Ray and Mittleman 2015 found that two weeks 
of music therapy significantly improved depression and agitation symptoms in nursing 
home residents with dementia.32 We believe that previous studies that did not include a 
waitlist control could have had their significance obscured or minimized by the effects of 
music listening, or other cognitively active control situations on the subjects, hence 
possibly obscuring effects of meditation. 
 KK and MBSR are the predominantly used meditation interventions in the 
literature. MBSR was not chosen for our study because it requires more hours of practice 
and a weekly group meeting,33 making it too dissimilar to our KK intervention. A major 
conflict of interest exists with studies solely focusing on KK interventions, because the 
Alzheimer’s Research and Prevention Foundation, which provides funding for many of 
these studies, promotes KK meditation. The Alzheimer’s Research and Prevention 
Foundation sells KK meditation CDs, MP3 files, and offers free practicing material on 
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their website, and supported the Newberg et al. 2010, Lavretsky et al. 2012, Moss et al. 
2012, Black et al. 2013 and other studies. This study aims to add the MFL group to 
potentially provide another meditation intervention for clinicians to introduce to patients. 
Finally, Newberg et al. 2010 suggested future studies employ larger samples, more 
groups, and a larger number of outcome measures,22 which the proposed study aims to 
address.   
VIII. Primary Outcome—Verbal Memory 
 
 The primary outcome variable is percent change from baseline performance on 
measures of verbal memory, operationalized by the CVLT-II, a well-validated and widely 
used test used to measure episodic memory in subjects with aMCI22,34 and suggested by 
Albert et al. 2011 for use in diagnostic and research outcomes in populations with 
aMCI.34 The CVLT-II is designed to test verbal episodic memory functions including 
encoding, delayed recall, and recognition.35,36 It takes 20 minutes to administer followed 
by a delay of 30 minutes to examine delayed recall.37 The encoding phase consists of 
reading a list of 16 words over five trials. Next, an interference list of words is read to the 
patient that they then recall followed by immediate and delayed recall of the first list and 
a yes/no recognition paradigm. Subjects will be randomly assigned to take the standard or 
alternate version to reduce practice effects.9 Subjects will take the other version at eight-
week follow up.  
The CVLT-II is a well-validated and widely used test used to measure episodic 
memory in subjects with aMCI.22,34 When compared with three other verbal memory tests 
using multivariate Cox regression analysis, CVLT-II is predictive of aMCI conversion to 
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AD.7 Additionally, Wang et al. 2013 found a positive association between the CVLT-II 
and DMN dysregulation.9 
IX. Secondary Outcomes 
 
 While the diagnosis of aMCI relies on subjects’ impairments in episodic memory, 
aMCI is known to be associated with multiple domains of cognition.3 Secondary outcome 
variables are designed to measure the effect, or lack of effect of these interventions on 
measures of verbal fluency, working memory, executive function, depression and 
anxiety. These will be measured with category fluency, letters C, F, and L fluency, TMT 
A and B, WAIS-IV Digit Span Test, RAID, and GDS. Percent change from baseline 
performance will be measured to determine differences in pre and post intervention 
testing. Albert et al. 2011 suggested these tests be used in populations with aMCI to 
examine deficits in cognitive domains outside of episodic memory.34 
IX.a Verbal Fluency 
Measures of phonemic (C, F, L) and semantic (animal) verbal fluency are 
validated and commonly used measures of verbal fluency in cognitively impaired adults 
including those with aMCI.6,22 As discussed previously, Mueller et al. 2015 found that 
people with aMCI have lower scores on both of these measures compared to cognitively 
healthy subjects.6 While diagnostically useful to differentiate normal aging from aMCI, 
these also represent a word finding deficit many patients with aMCI encounter from early 
stages of their disease process. Animal naming reflects semantic fluency while Letter C, 
F, and L naming reflects phonemic fluency. Semantic fluency is thought to be more 
impaired in subjects with aMCI due to greater impairment of semantic categorization 
compared to phonemic fluency. 
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IX.b Working Memory 
 
 The WAIS-IV Digit Span Test is a measure of working memory that includes 
attention, encoding, and mental flexibility.3,14 It has been used as an outcome in 
meditation studies in people with aMCI previously.16 Subjects repeat increasingly long 
sequences of digits beginning with practice trials increasing to nine digits forwards and 
backwards. For this study, the measure is determined by the difference between the 
scores for sequencing forwards and backwards digit spans.  
IX.c Executive Function 
 
Trail Making Tests A and B are measures of mental flexibility, and also examine 
set-shifting ability, both features of executive functioning.3,14 Trail Making Test A 
requires subjects to connect circles with numbers 1-25 as fast as possible. Trail Making 
Test B is more difficult, and subjects must connect a sequence of numbers and letters in 
the following pattern: 1-A-2-B-3-C. This study will use the difference in time to 
completion of tests A and B as the outcome measure.  This scoring technique for the Trail 
Making Tests has been found to have 64% sensitivity for predicting conversion of MCI to 
AD, and is therefore sensitive to the changes that are specific to aMCI.38 Newberg et al. 
2010 also found a correlation between improved Trails B time and increased PFC 
cerebral blood flow on SPECT imaging in the KK meditation group.16  
IX.d Anxiety and Depressive Symptoms 
 
The RAID and GDS are measures of anxiety and depressive symptoms, 
respectively, tailored for use in the elderly population. These measures are used as 
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screening tools to evaluate elderly subjects with anxiety or depressive symptoms,10 and 
also as markers of mood symptoms as they change over time.9  
X. Justification for Study Design 
 
Study population, including exclusion and inclusion criteria, is sourced from the 
literature.10 Our study population inclusion criteria will consist of patients aged (1) 65-85 
with an MMSE score  26,21 (2) who meet Petersen criteria for aMCI,39 (3) have SPECT, 
PET, or MRI imaging suggesting or consistent with AD pathology,34 (4) proficiency with 
English language,24 and (5) have at least a high school diploma. Exclusion criteria 
includes (1) prior traumatic brain injury (TBI),3,9 (2) prior cerebral vascular accident 
(CVA),3 (3) comorbid psychiatric, medical, or neurological conditions,9,10 (4) alcohol 
abuse,13 (5) prior/current brain neoplasms,10 (6) projected <1 year life expectancy, (7) 
prior meditation experience >1 year, (8) concurrent enrollment in another study. These 
criteria and projected power of the study aim to create a population that can be 
generalized to people living in the Northeast United States with aMCI, while reducing 
confounding variables that could affect outcome measures.  
 Our subjects will be randomized to the four groups. While other studies have 
used age- matched controls,10 or matched we aim to reduce subject bias and enhance 
internal validity through randomization. Adherence will be ensured using a daily log of 
adherence to practice similar to the procedure of Lavretsky et al. 2012,30 and an 
additional weekly phone call to check in on compliance for the MFL, KK, and music 
listening groups.  
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XI. Statistical Methods 
XI.a Sample Size 
 
 Small sample size is a common limitation to the current literature on meditation 
interventions in cognitive impairment. This study’s sample size calculation was derived 
from the Moss et al. 201230 and Newberg et al. 201016 studies described previously. Moss 
et al. 2012 used 15 subjects with varying degrees of memory problems in an eight-week 
KK intervention, and derived statistical significance on several parameters.29 The 
Newberg study used three populations with differing levels of cognitive impairment, with 
total 14 subjects, also reaching significance on several outcomes.22 Both studies cited 
small sample size as major limitations, and subjects groups had less than eight subjects 
per group. Data from the Newberg et al. 2010 study were used to determine effect size 
and sample size. Effect size () was calculated at 11. The PS: Power and Sample Size 
Version 3.1.2 software, an -value of 0.05, power of 80%, a  of 6.3 (conservative 
estimate), and m=1 for the independent t-test, generated an initial n=24 (Appendix C). 
After Bonferroni Correction, to control for multiple comparisons, the sample size was 
adjusted to n=40. A conservative 25% drop out rate,22,30-31 increased the number to n=50. 
To make the groups even, the total number of participants was increased to 52, to make 
four groups of 13.  
XI.b Statistical Tests 
 
 Outcomes will be measured as percent change from baseline, which is consistent 
with the Newberg et al. 2010 study.16 Significance will be 0.05 for all tests. Consistent 
with several studies of cognition after meditation intervention, we will use a within-
subjects repeated measures multivariate analysis of covariance (MANCOVA) for the 
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CVLT-II, phonemic and category naming, TMT A and B, WAIS-IV Digit Span Test, 
RAID, and GDS as dependent variables.18,30 Age, gender, MMSE, and education level 
serve as covariates in this model for each outcome. A MANCOVA analysis will help 
protect against Type I errors, compared to multiple ANCOVA analyses. A paired T-test 
cannot be used, because the study is designed with more than two groups, unlike the 
Moss et al. 2012 and Newberg et al. 2010 studies, which used only two groups. While 
participants will be randomized, statistical corrections will be performed if baseline 
characteristics of age, gender, MMSE, and education level between groups significantly 
differ, which could affect the results. Post-hoc tests will be performed as needed to 
examine possible interactions from all model outcomes. IBM SPSS Statistics will be used 
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CHAPTER THREE—STUDY METHODS 
I. Study Design 
 
 This study is a prospective, single center, randomized clinical trial to study two 
interventions, Kirtan Kriya and Mindfulness meditation, on measures of verbal memory, 
specifically semantic categorization, compared to music listening and wait list controls. 
Secondary outcomes include measures of verbal fluency, executive function, working 
memory, anxiety, and depression. Percent change from baseline scores within groups is 
the outcome measure. Participants will be computer randomized into KK, MFL, music 
listening, or wait list groups so baseline characteristics are not statistically different. 
II. Study Population and Sampling 
 
 52 community-dwelling male and female patients will be recruited from Yale 
Memory Clinic and Yale Alzheimer’s Disease Research Center. See Table 1 for inclusion 
and exclusion criteria. Randomization aims to create groups so that baseline 
characteristics between groups will not be statistically different, but if groups 
significantly differ, demographic variables (age, MMSE score, education level, gender) 









Inclusion Criteria Exclusion Criteria 
Age: 65-85 Prior TBI7,8 
Diagnosis of aMCI1 Prior CVA3 
Imaging consistent with neuropathological findings of AD2-6 
English proficiency 
 
MMSE score  26 
Comorbid conditions7,9 
Concurrent enrollment in other study 
>1 year meditation experience 
High school education Alcohol abuse13 
 
Prior/current brain neoplasms9 
 
<1 year life expectancy 
Table 1. Inclusion and Exclusion Criteria 
III. Subject Protection and Confidentiality 
 
The Yale Human Investigation Committee (HIC) will approve the study, along 
with HIC approval. Prior to enrollment, volunteer participants will sign an informed 
consent form (Appendix D).  This form contains information explaining the potential 
benefits, risks, and reasons for performing the study, as well as a timeline of the trial. It is 
clearly stated that participation is voluntary, and a participant is free to discontinue 
participation at any time. Participants will not be compensated for their participation, and 
will not be charged for clinician visits pertaining to the study. All employees involved in 
the study will complete HIPAA training certification and Human Subjects Protection 
training.  Additionally, the Yale HIC will approve all study materials including consent 
forms and any study flyers or announcements. 
All patient information will be used exclusively for this research study, and will 
be maintained according to guidelines set forth by HIPPA and the United States 
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Department of Health and Human Resources.  Printed material will be secured in a filing 
cabinet at the researcher’s office in New Haven, CT accessible only to study researchers. 
Digital information will be stored on an encrypted and password-locked computer that is 
only accessible to the Lead Investigator.  Each patient will receive a computer generated 
random 10-digit code to replace his/her identifying information. The data will only be 
identifiable by code to investigators involved.  
IV. Recruitment 
 
 Recruitment will last six months prior to initiation of the study. Patients will be 
recruited through clinician recommendation from the Yale Memory Clinic and self-
referral through flyers and advertisements posted around Yale New Haven Hospital 
System (Appendix E). Clinician referral will attempt to decrease selection bias caused by 
self-referral through advertising. After a patient is referred, a research assistant will call 
the patient to explain the opportunity to participate in a research study. If interested, an 
appointment of approximately one hour will be scheduled to conduct baseline assessment 
following the six-month recruitment period and group randomization. At this 
appointment, participants will be formally enrolled, perform baseline testing, and learn 
their intervention if applicable.  
 We aim to yield a larger total study population to increase the power of our 
results, as lack of power has been a significant problem with previous studies exploring 
meditation in MCI and AD. While other studies of subjects with aMCI employed groups 
with an average total number of 13 participants, we aim to have 13 participants in each 
arm of the study, which is larger than other meditation studies exclusively focusing on 
subjects with aMCI.  
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V. Study Variables and Measures 
 
 We will employ two meditation interventions, one active control, and one wait list 
control. The meditation interventions will be KK and MFL. The active control will be 
music listening, and the wait list control will have no further intervention. Participants in 
the KK group will watch a ten-minute instructional video on how to practice KK 
meditation, and then show a researcher how to perform the meditation to demonstrate 
proficiency. They will be given Appendix A as a visual aid and a CD of guided KK 
meditation to listen to for 12 minutes/day for eight weeks at their convenience. 
Participants in the MFL group will watch a ten-minute instructional video on how to 
practice MFL meditation, and teach back the instructions to a researcher to demonstrate 
proficiency. They will return home with Appendix B and a MFL guided meditation CD 
to practice 12 minutes/day for eight weeks. Participants in the music control group will 
listen to Wolfgang Amadeus Mozart concertos for 12 minutes/day for eight weeks 
consistent with the protocols by Moss et al. 20121 and Newberg et al. 2010.2  
 The primary outcome is percent change from baseline scores on measures of 
episodic memory using the CVLT-II, specifically verbal recall (total, immediate, and 
delayed) and semantic categorization. Secondary outcomes include percent change from 
baseline scores on Animals Fluency and Letters C, F, L Fluency measuring semantic and 
phonemic fluency, respectively, as well as WAIS-IV Digit Span Test, TMT A and B, 
GDS, and RAID Scale to assess working memory, executive function, and symptoms of 
depression and anxiety. 
VI. Blinding of Intervention/Outcome 
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 Due to the nature of the interventions, the study will not be completely blinded. 
The researcher responsible for distributing the computer-generated randomizations will 
be blinded. A blinded researcher will conduct the pre and post neurocognitive test 
administration and subsequent data collection and analysis, identifiable only by the 10-
digit code. Due to the nature of the study, the participants will not be blinded to their 
intervention. A non-blinded researcher will ensure intervention performance competence 
and call participants weekly. This researcher will also be responsible for answering the 
emails and calls of patients. This researcher will not be a part of data collection or 
analysis. 
VII. Assignment of Intervention 
 
 Patients will be randomized to one of the four groups at the end of the 6-month 
recruitment period. Possible confounding baseline variables include age, gender, MMSE 
score, baseline test performance, and education level. An analysis will be performed to 
examine for group differences. If significant, these demographic variables will be 
adjusted for in the statistical analyses. 
VIII. Data Collection 
 
 Following the recruitment and enrollment period, participants will perform 
baseline neuropsychological testing of the CVLT-II (total recall trials 1-5, immediate 
recall, delayed recall, semantic categorization), WAIS-IV Digit Span Test, Categories 
(Animals) and Letter C, F, and L Fluency, TMT A and B, GDS, and RAID scale. Next, 
they will undergo training for the intervention, followed by teach back for the meditation 
groups. At the eight-week follow up visit the tests will be re-administered. After 
intervention is complete, patients may keep the meditation or music CD. Data will be 
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identifiable only by the 10-digit code assigned to each participant. A blinded research 
assistant will enter the test scores into the encrypted computer database. 
IX. Adherence 
 
 The participants will be provided with a daily diary to record the time they 
performed the intervention each day to ensure adherence. A researcher will call the 
patient within the first five days, and then weekly to ensure compliance with the 
intervention. Participants will be given a phone number and email address of the non-
blinded investigator to contact with questions at any time. Wait list participants will not 
be contacted.  
X. Monitoring Adverse Events 
 
 Clinicians not involved in the research will monitor for adverse events, however, 
these are atypical in meditation studies. Researchers will monitor for adverse or 
unexpected experiences, which could include depression, anxiety, boredom, confusion, 
and disorientation according to one study reporting the negative possible effects of 
meditation.3 If an adverse experience occurs, the participant may withdraw from the 
study at any time.  
While the study has several measures to ensure privacy and data protection, an 
unintended release of information or hack of medical information is still possible, and 
will be promptly managed with assistance from the Yale Information Technology 
Services. In such an event, participants will be notified promptly of the release of their 
medical or other sensitive information.   
XI. Sample Size Calculation 
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 Sample size calculation was performed using PS: Power and Sample Size Version 
3.1.2 software. Sample size calculation has been estimated to be n=52, with 13 
participants per group. This number was based on the study by Newberg et al. 2010,2 
which also determined a power () of 11 and standard deviation difference (conservative 
estimate, ) of 6.3.  Initially with a type 1 error of 0.05 (), the calculation yielded six 
participants per group (total n=24), however the Bonferroni Correction estimate increased 
the calculation to total group size of 40. This number was adjusted to account for a 25% 
drop out rate, consistent with the literature,2,4,5 ultimately yielding 13 participants per arm 
of the study, and total of 52 subjects. This study’s sample size is larger than previously 
published similar studies whose results lacked power due to small samples.1,6  
XII. Timeline 
 
 The study, including analysis, writing, and publication submission, will be 
completed within the 24-month deadline, starting June 30, 2016 with patient recruitment. 
The actual study, from enrollment to completion of follow up testing, will take nine 
months. See timeline below (Figure 1). Patients will be enrolled during the first 
appointment. Following the 6-month recruitment period, participants will be called back 
for baseline testing and to learn their intervention for the KK, MFL, and music listening 
groups. Wait list groups will be brought back for baseline testing only. The order of the 
tests will be: CVLT-II Short Recall, WAIS-IV Digit Span, Trail Making Test A and B, 
CVLT-II Delayed Recall, Animal Naming, and Letter C, F, L Fluency. Data collection 




Figure 1. Timeline 
XIII. Resources 
 
 We will have a secure computer for data entry and code generator to produce the 
patient’s secure number code. The data will be stored on an external hard drive. The 
computer and external hard drive will be passcode protected. The passcodes must be 
changed every 6 months. The hard copies of the tests and baseline demographic sheet 
will be stored in folders identified with the patient’s numerical code in a locked filing 
cabinet. All other identifying information will be removed. A secure office in the Yale 
Memory Clinic will be used to conduct the neuropsychological testing. 
 The instructional videos on the meditation will be delivered on a computer that 
can access YouTube. Compact discs will be given to the patients in the three active 
groups containing the audio recording of their guided meditation or music. Participants 
without a portable CD player and/or headphones will be given them. Funding for these 
















Baseline Testing and 
Intervention 
Assignment










1. Moss AS, Wintering N, Roggenkamp H, et al. Effects of an 8-week meditation 
program on mood and anxiety in patients with memory loss. Journal of 
alternative and complementary medicine (New York, N.Y.). Jan 2012;18(1):48-
53. 
2. Newberg AB, Wintering N, Khalsa DS, Roggenkamp H, Waldman MR. 
Meditation effects on cognitive function and cerebral blood flow in subjects 
with memory loss: a preliminary study. Journal of Alzheimer's disease : JAD. 
2010;20(2):517-526. 
3. Craven JL. Meditation and psychotherapy. Can J Psychiatry. Oct 
1989;34(7):648-653. 
4. Marciniak R, Sheardova K, Cermakova P, Hudecek D, Sumec R, Hort J. Effect of 
meditation on cognitive functions in context of aging and neurodegenerative 
diseases. Front Behav Neurosci. 2014;8:17. 
5. Lavretsky H, Epel ES, Siddarth P, et al. A pilot study of yogic meditation for 
family dementia caregivers with depressive symptoms: effects on mental 
health, cognition, and telomerase activity. International journal of geriatric 
psychiatry. Jan 2013;28(1):57-65. 
6. Khalsa DS. Stress, Meditation, and Alzheimer's Disease Prevention: Where 





I. Advantages and Limitations  
 
Our study poses several advantages to previous studies, and aims to expand upon 
the current literature on meditation interventions in aMCI. First, we will use an inactive 
and active control group. Control group choice is a difficult aspect of research design in 
this field, and many studies have attempted to mitigate problems associated with one type 
of control group. For example, studies only using an active control could have trouble 
reaching significance because the control activity could also cause changes in cognition 
or brain activity on imaging. While studies using this control method cite this as a benefit 
to determine the unique cognitive effects of meditation, it is also a disadvantage, as we 
have previously described benefits of music listening in elderly people with memory 
complaints.  
Studies that only use an inactive control group have difficulty attributing all of 
their findings to meditation alone, instead of the effect of introducing any intervention to 
a subject with aMCI. Known benefits of performing an intervention could include subject 
bias of expecting an effect after performing the intervention, but could be expanded to 
possible benefits gained by performing a daily routine, subjective feelings of purpose as a 
participant in a study, access to significant relationships, all found to improve quality of 
life in senior citizens.1 For example, subjects in the MFL intervention and 
psychoeducation intervention in the Smart et al. 2016 both self-reported improved 
memory, cognition, and no significant difference on measures of depression between 
groups.2 
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Another advantage to our study is the specific inclusion and exclusion criteria to 
make a homogenous population. Previous studies used participants with varying degrees 
of cognitive impairment, or AD and aMCI, or had a diagnosis of aMCI that was only 
clinical. This study will solely focus on subjects with aMCI as diagnosed by clinical 
data3,4 and neuroimaging suggestive of AD neuropathology.5 We exclude a variety of 
confounders including prior stroke, alcohol abuse, malignancy, or prior traumatic brain 
injury. These exclusion criteria are consistent with the literature, and combined with the 
specific inclusion criteria will likely lead to a more homogenous aMCI sample. This 
sample population will also be much larger than previous studies, with the aim of 
achieving larger effect sizes. 
 The purpose of this study is to examine the effectiveness and feasibility of two 
interventions on cognitive outcomes, but it does not include neuroimaging as an outcome. 
In follow-up studies, we intend to use information gained from this study to design a 
study that would examine the effects of meditation interventions on the DMN with 
neuroimaging, as well as enlarge the neuropsychological testing battery. However, this 
study will require less funding because it does not include imaging, which is beneficial 
for a preliminary study. Another future direction could examine the longevity of the 
impact of meditation on the brain, and could provide more information on disease 
progression within the aMCI population throughout all of our participants.  
Another limitation to this study is using a relatively large number of outcomes 
with several neuropsychological tests, which lends the possibility of finding effects 
reaching significance on chance alone, especially in the setting of our relatively small 
 48 
sample size. The Bonferroni Correction was used to mitigate this effect, but it still poses 
a threat to validity. 
This study will recruit participants partially through self-referral, which 
introduces the possibility of subject bias. We are hoping to mitigate this effect with 
randomization of participants and physician referral for recruitment, but the threat still 
exists. It is impossible to blind our participants; therefore knowledge of group could 
affect participants’ subsequent testing and reporting of mood symptoms. We aim to 
address this by treating groups as equally as possible, and blinding the investigators 
involved with data analysis. We also have a dedicated researcher who is non-blinded who 
will perform the follow-up phone calls, and will not be a part of data analysis. 
A final limitation to any study involving meditation is that it is inherently difficult 
to ensure true compliance. This study has several measures in place to ensure adequate 
compliancy, including a teach back for proficiency, weekly compliance phone calls, and 
a daily log to ensure proficiency and compliance, but ultimately it is difficult to ensure 
participants are putting effort into meditation during the practices. However, the 
voluntary nature of our study will hopefully protect against this, since participants are 
choosing to be involved.  
II. Clinical and Public Health Significance 
II.A Economic Impact 
 
People with AD become increasingly dependent on others for basic tasks like 
driving and paying bills, but ultimately progress to relying on caretakers for all activities 
of daily living, including feeding, bathing, and dressing.4 AD and other dementias are 
estimated to cost the United States $226 billion in 2015 for the hospitalization, long-term 
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facilities, and hospice care for people with dementia. In 2050, this cost is projected to 
increase to $1.1 trillion. 
Before institutionalization, many people with AD are cared for in their home or a 
family member’s home.6 Often, their caregivers are family members, usually females 
(66%) with college degrees (40%). They are rarely compensated for their work, and cite 
caregiving as their primary barrier to gaining other employment. Last year, 15.5 million 
people provided 17.7 billion hours of unpaid care, valued at $220.2 billion.4 These 
caregivers are unable to participate in the paid workforce, leaving them economically 
disadvantaged. The recently published 2016 Facts and Figures from the Alzheimer’s 
Association reports that 48% of caregivers’ families report the costs associated with 
providing for their loved one affects their ability to pay for basic needs.4 While the 
burden is largely on spouses and daughters, it is also estimated that 250,000 children age 
eight to eighteen provide care for a family member with AD.  
 Importantly, a one-year delay of AD development from aMCI would result in 
nine million fewer cases by 2050.4 This would also lessen caregiver burden, as it would 
increase the amount of time the patient is capable of performing tasks independently. 
This would have significant impacts on quality of life for the individual, and decrease 
costs and burden on the healthcare system, economy, and caregivers. 
II.B Morbidity and Mortality 
 
 While most people diagnosed with AD die within a decade of diagnosis, many live 
for much longer after initial memory complaints emerge.2 AD is ranked as the 12th most 
burdensome disease in respect to reducing a person’s healthy and disability free years. This 
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number has increased drastically since 1990, when it was the 25th most burdensome 
disease.  
The Alzheimer’s Association estimates that 61% of people over the age of 70 with 
AD will die before age 80.2 In contrast, people over the age of 70 without AD have a 30% 
risk of death before 80. Additionally, deaths attributed to AD, meaning they were unlikely 
to have occurred without the presence of AD, has increased 71% since 2000. While this 
increase could be related to an increase in citing AD as cause of death on death certificates, 
it is notable both in regards to disease burden and the incidence in the growing aging 
population. 
 III. Importance of the Proposed Study 
 
 Our proposed study targets a population with amnestic mild cognitive 
impairment, which is a frequently used group for interventions to slow cognitive decline 
and delay institutionalization.6 As described previously, delay of institutionalization by 
only a year relieves an enormous economic burden on the health care costs within the 
country’s rapidly growing elderly population.2 Additionally, quality of life is closely 
associated with a person’s independence, and perceived to decrease upon 
institutionalization.1  
 Meditation is a promising intervention studied in the context of many disease 
processes.7,8 Materials, if any, are low cost, which benefits both the patient and insurer. 
Meditation is associated with minimal risks, and does not have any known negative side 
effects. After the practice is learned, meditation can be used at any time or place and 
requires no additional materials. Meditation is additionally advantageous compared to 
other non-pharmaceutical interventions especially in aging populations, because unlike 
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exercise or yoga, it requires none or very little physical abilities. This is important in the 
context of an aging population whose physical limitations advance with age and disease 
state. For KK meditation, one must only move their fingertips, while mindfulness does 
not require any purposeful movements. MFL provides an additional advantage, as it 
could be more appealing to an elderly demographic who could be averse to practicing a 
chanting meditation. From a caregiver’s perspective meditation is an ideal intervention 
because the patient can perform it completely independently and at their leisure, with no 
supervision or set up required. 
 We designed this study to have a primary outcome on measures of verbal 
memory, a facet of episodic memory, because it is typically the first aspect of cognition 
impaired in people with aMCI.9 We believe that if we focus on the first affected aspects 
of cognition, we will hopefully enable us to see the greatest improvements with an 
intervention. We aim to possibly help people slow their cognitive decline through 
meditation, build compensatory capabilities, reduce the expression of the disease and 
other domains of cognition including attention, processing speed, and executive 
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APPENDIX A: Kirtan Kriya Meditation Instructions 
1. Repeat the Saa Taa Naa Maa sounds (or mantra) while sitting with your spine straight. Your 
focus of concentration is the L form, while your eyes are closed. With each syllable, imagine 
the sound flowing in through the top of your head and out the middle of your forehead (your 
third eye point). Start the CD when you are ready. It will cue your transitions. 
2. For two minutes, sing in your normal voice. 
3. For the next two minutes, sing in a whisper. 
4. For the next four minutes, say the sound silently to yourself.  
5. Then reverse the order, whispering for two minutes, and then out loud for two minutes, for a 
total of twelve minutes. 
6. To come out of the exercise, inhale very deeply, stretch your hands above your head, and 
then bring them down slowly in a sweeping motion as you exhale.  
The mudras, or finger positions, are very important in this kriya (see illustration below). 
 
• On Saa, touch the index fingers of each hand to your thumbs. 
• On Taa, touch your middle fingers to your thumbs. 
• On Naa, touch your ring fingers to your thumbs. 







APPENDIX B: Mindfulness Meditation Instructions 
 
1. Sit in a comfortable position with spine straight. 
 
2. Focus your concentration in an L form (see Illustration below) with your thoughts 
entering through the top of your head, and exiting through your mouth on 
expiration. 
 





























Initial Sample Size:  6 x 4 groups = 24 total participants 
• After Bonferroni Correction for multiple comparisons N= 10/group; 
total N=40 
• Drop Out Rate (25%)= 40 x 0.25= 50  









APPENDIX D: INFORMED CONSENT FORM 
 
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT 
200 FR. 1 (2014-4) 
 
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL 
 
Study Title: Meditation Interventions in Amnestic Mild Cognitive Impairment 
Principal Investigator: Emily K. Richards, PA-S; Emily Sharp, PhD. 
Funding Source: Yale School of Medicine 
 
Invitation to Participate and Description of Project 
 
You are invited to participate in a research study designed to examine the effect of a 
meditation intervention practiced over 8 consecutive weeks on cognitive outcomes and 
measures of anxiety and depression. 
 
In order to decide whether or not you wish to be a part of this research study you should 
know enough about its risks and benefits to make an informed decision.  This consent form 
gives you detailed information about the research study, which a member of the research 
team will discuss with you.  This discussion should go over all aspects of this research: its 
purpose, the procedures that will be performed, any risks of the procedures, and possible 
benefits. Once you understand the study, you will be asked if you wish to participate; if so, 
you will be asked to sign this form. 
 
Description of Procedures 
 
If you agree to participate in this study, you will be designated to an intervention group, an 
active control, or wait-list control group.  Those in the intervention groups will learn one 
of two forms of meditation to be practiced for 12 minutes/day. The active control group 
will listen to a music CD for 12 minutes/day. Those in the intervention and active control 
groups will learn and perform their intervention on the same date as baseline testing. The 
interventions can be performed from home at a time of your choosing. Weekly phone calls 
will be made to your home to ensure compliance with performing the intervention and 
answer any questions you have. You will also be asked to record the time of your 
intervention on a daily log. At the end of the 8 weeks, you will return to the clinic for follow 
up testing. You may keep the materials given to you at the beginning of the program.  
 
Content: 
The cognitive tests will measure verbal memory, working memory, executive function, 
global cognition, and anxiety and depressive symptoms. 
 
Participation time: 
Total length of participation is up to 9 months, however six of those months include the 
total recruitment period before the possible intervention begins. If assigned to an 
intervention or active control, participation is 12 minutes/day for 8 weeks. The cognitive 
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testing is estimated to take 1 hour total, and will occur at the start and end of the 8 weeks. 
See Timeline below.  
 
Risks and Inconveniences 
 
There are no known physical risks associated with this study.  However there is the possible 
risk of loss of confidentiality.  Every effort will be made to keep your information 




You may learn to perform an evidence-based meditation intervention. Meditation has 
been practiced for thousands of years and is associated with many measures promoting 
enhanced well-being. Participation in this study may allow researchers to identify a 
meditation intervention that may improve cognitive function in people with amnestic 
mild cognitive impairment, and potentially slow progression to dementia. This would 
allow clinicians to prescribe a cost effective, non-pharmaceutical adjunctive therapy for 





No financial compensation is offered in this study. You may keep the materials provided 




Any identifiable information that is obtained in connection with this study will remain 
confidential and will be disclosed only with your permission or as required by U.S. or 
State law.  Examples of information that we are legally required to disclose include abuse 
of a child or elderly person, or certain reportable diseases.  All participants will be 
identified to researchers as an identification number only. Information obtained 
throughout this study and any topics discussed via the online forum will be held strictly 
confidential and will be in compliance with the Health Insurance Portability and 
Accountability Act (HIPAA) of 1996.  Researchers will be required to successfully 
complete HIPAA training through Yale University and research information will only be 
accessible on encrypted devices that are also password protected.  Any physical 
documentation that may be created throughout the course of the study will be identified 
by the assigned identification number only and will be stored in locked file cabinets in a 
secure room on the Yale University campus. When the results of the research are 
published or discussed in conferences, no information will be included that would reveal 










Representatives from the Yale Human Research Protection Program, the Yale Human 
Investigation Committee (the committee that reviews, approves, and monitors research on 
human subjects) may inspect study records during internal auditing procedures.  However, 
these individuals are required to keep all information confidential.  
 
Voluntary Participation and Withdrawal 
 
Participating in this study is voluntary. You are free to choose not to take part in this 
study.   Refusing to participate will involve no penalty or loss of benefits to which you 
are otherwise entitled (such as your health care outside the study, the payment for your 
health care, and your health care benefits).  However, you will not be able to enroll in this 
research study and will not receive study procedures as a study participant if you do not 
allow use of your information as part of this study. You do not give up any of your legal 
rights by signing this form. 
 
If you do become a subject, you are free to stop and withdraw from this study at any time 
during its course.  To withdraw from the study, you can call a member of the research 
team at any time and tell them that you no longer want to take part.  This will cancel any 
future appointments.  The researchers may withdraw you from participating in the 
research if necessary.  Developing any of the exclusion criteria may lead to removal from 
the study. 
 
Withdrawing from the study will involve no penalty or loss of benefits to which you are 
otherwise entitled.  It will not harm your relationship with your own doctors or with Yale-
New Haven Hospital. If assigned to either control group, you will have the opportunity to 
obtain the meditation materials at the conclusion of the study if you so choose. 
 
When you withdraw from the study, no new health information identifying you will be 
gathered after that date.  Information that has already been gathered may still be used and 
given to others until the end of the research study, as necessary to insure the integrity of 




We have used some technical terms in this form.  Please feel free to ask about anything 
you don't understand and to consider this research and the consent form carefully – as long 





I have read (or someone has read to me) this form and have decided to participate in the 
project described above.  Its general purposes, the particulars of my involvement and 
possible hazards and inconveniences have been explained to my satisfaction.  My 





      








Signature of Principal Investigator  Date 
  
                                      or 
 
___________________________________________ ___________________ 
Signature of Person Obtaining Consent  Date 
 
 
If you have further questions about this project or if you have a research-related problem, 
you may contact the Principal Investigator Emily Richards PA-SII (717) 512-4617.  
If, after you have signed this form you have any questions about your privacy rights, 
please contact the Yale Privacy Officer at (203)-432-5919. If you would like to talk with 
someone other than the researchers to discuss problems, concerns, and questions you may 
have concerning this research, or to discuss your rights as a research subject, you may 
contact the Yale Human Investigation Committee at (203) 785-4688. 
 
THIS FORM IS NOT VALID UNLESS THE FOLLOWING BOX 
HAS BEEN COMPLETED BY THE HIC OFFICE 
 
 







APPENDIX E: RECRUITMENT FLYER 
Research Trial Opportunity 
 
We are recruiting healthy participants, ages 65-85 with amnestic mild cognitive 
impairment for a study on meditation 
 While there is no compensation, you have the opportunity to learn and practice a 
meditation for eight weeks in your home, at your convenience.  
Meditation is known to help reduce symptoms of anxiety, depression, and improve 
thinking ability and concentration. 
Contact your clinician to see if you are eligible for this study, or contact Emily Richards 
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